ML18 is primarily utilized in research settings for its role as a selective antagonist of the GPR55 receptor, a cannabinoid-related receptor. It is particularly valuable in studying the physiological and pathological functions of GPR55 in various biological systems. Researchers use ML18 to investigate its potential implications in conditions such as cancer, pain management, and metabolic disorders. Its ability to modulate GPR55 activity makes it a useful tool for understanding receptor signaling pathways and developing targeted therapies. Additionally, ML18 is employed in preclinical studies to explore its effects on inflammation and neuroprotection, offering insights into its therapeutic potential.